As the healthcare landscape continues to shift, medical providers and hospitals are continuously being challenged to develop clear and concise visions and redesign care delivery in ways that will usher proper transitions to value-based care. As value-based healthcare continues to take root, more and more hospitals and providers are finding themselves with little option but to join the movement. However, the jump from previously utilized fee-for-service models to value-based healthcare is not an easy one, and many healthcare organizations are finding it difficult to do so. The greatest challenge lies in successfully making the transition from volume to value-based healthcare in ways that are financially stable. Such inherent difficulties faced by those within the healthcare system are what have necessitated strategic
2. What are the constraints? There are budget and time constraints. The discovery and development of drugs risky process that can consume a lot of time and money. The longer it takes to get develop a new drug, the more money it will cost and if the drug ends up harming participants that test new drugs, that will be a lot of money down the drain.
1. Introduction Population ageing is a problem that a lot of developed countries have to face. The more and more advanced medical treatment and technology not only but our life better, but also make our life expectancy rising. Also, the birth rate of most of the developed countries is declining. The median age of a country rise and it causes the phenomenon of Population ageing occur.
Scope This review will focus on the similarities and challenges related to Advance Care Planning (ACP). Introduction ACP is a relatively important topic that aids general public to make a more informed decision regarding their healthcare with a more educated population and the increasing acceptance for patient autonomy, as well the advanced medical technology that increases the average life expectancy as a result. ACP is defined as a continuous process whereby the patient’s wishes regarding medical treatments and end-of-life care are clearly discussed and documented down to be used should the individual become incapacitated in decision-making (Ng, 2009). The topic of ACP has not been widely accepted and practiced locally compared to westernized
According to a report by the World Health Organization, the number people above 65 years of age is projected to grow from an approximate 524 million in the year 2010 to about 1.5 billion in 2050 (2). The increase in population aging has had notable impacts on the health sector and the economy in the world as is discussed in this essay. Drivers of population aging The age and size of the composition of a population are determined by three demographic processes namely trends in life expectancy, mortality, and fertility. Declining fertility rates is the chief driving force behind the increase in the population of the elderly. Currently,
), Ph.D. (Per.) SPPU, Pune ________________________________________ Introduction: Face-to-face promotion is the dominant promotion tool for pharmaceutical, medical equipment and biotechnology companies. However, there is a growing level of discomfort with the current selling model. It is incredibly expensive and inefficient.
Henceforth the different states will determine whether to accept or decline the federal organisation funds for extensions and advance the states healthcare programs. In most cases the obamacare will negatively affect the states because the costs of healthcare will be more expensive and the rising of private insurance. This will be expensive for the people living in those states to afford the private insurance especially for those relying on employers for insurance.
This is because the elimination and reduction of duties for the textile and apparel products will provide better access to new market such as US, Canada, Mexico and Peru. 4. Possible industry at disadvantage and badly effected The industry that might be badly affected is the pharmaceutical industry because of the strict intellectual property laws by the TPPA. The intellectual property (IP) rules will rise the patent and data protections for pharmaceutical companies, the price of medicines will increase incredibly high as well as the prevention of generic drugs into the market. Therefore it will be a critical situation to the pharmaceutical companies because they might be cannot afford the skyrocketing cost of medicine for serious illness such as AIDS and cancer.
Between September 2010 and April 2011, the implementation of the health sector measures continues with the Minister Loverdos who raises the cost of the tickets and then introduces, for people without health insurance, the entire payment of all care at the expense of the citizen. At the same time, the budget of public hospitals was cut by 26%. As a result, the staff’s amount of work increased and waiting lists got longer. [KENTIKELENIS, A, et al(2011)] The reforms also concerned the pharmaceutical expenditure; the target was the reduction in the spending from €4,37 billion in 2010 to €2,88 billion in 2012 and to €2 billion by 2014. But many unexpected results were produced: some drugs became unavailable as a consequences of delays in reimbursement for pharmacies, which were becoming over-indebted; moreover, pharmaceutical companies reduced supplies because of unpaid bills and low profits.
Another problem with combating healthcare fraud abuse is the cost. Trying to prevent fraud is a costly challenge for organizations. Most organizations try to combat fraud by using their in house technology tools. Which is ok but the problem is some of the tools are outdated and need to be upgraded in order to be more efficient. The direct targets of fraudulent billing practices are private health payers and government-funded health plans.